Please assess the completion status of the following clinical trial:

Trial Title: Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Barrett esophagus, meeting all of the following criteria:~  * Presence of specialized columnar epithelium anywhere in the tubular esophagus with ≥ 2 cm of circumferential involvement~ * No evidence of high-grade dysplasia or cancer by esophagogastroduodenoscopy (EGD)~ * No prior histologically confirmed esophageal dysplasia, including cancer~* Adequate Barrett mucosa, defined as ≥ 4 of 8 research samples with≥ 50% intestinal metaplasia in research biopsies~* No ulcer, erosion, plaque, nodule, stricture, or other luminal irregularity within the Barrett's segment or erosive esophagitis (Los Angeles classification \> grade A) detected at pre-intervention EGD exam~* Eastern Cooperative Group (ECOG) performance status 0-2~* Hemoglobin normal~* Platelet count ≥ 100,000/mm³~* Aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Bilirubin ≤ 2.5 times ULN~* Creatinine ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No nasal polyps associated with asthma or induced or exacerbated by aspirin~* No malignancy within the past 5 years except for nonmelanoma skin cancer~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents or rescue medication~* No history of endoscopically or radiographically diagnosed peptic ulcer disease (bleeding or nonbleeding)~* No other uncontrolled illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Bleeding disorder~ * Vitamin K deficiency~ * Alcohol abuse (defined as ingestion of ≥ 3 drinks per day)~ * Psychiatric illness or social situations that would limit study compliance~* At least 3 months since prior chronic use (defined as ≥ 7 days during the 3 months preceding the beginning of the Run-in phase) of acetylsalicylic acid (aspirin), nonsteroidal antiinflammatory drug (NSAIDs), or selective cyclooxygenase (COX-2) inhibitors~* At least 3 months since prior investigational agents except innocuous agents with no known interaction with the study agents (e.g., standard dose multivitamins or topical agents for limited skin conditions)~* No prior fundoplication, bariatric surgery, or any other major upper gastrointestinal surgery~  * Prior cholecystectomy allowed~* No other concurrent NSAIDs (including aspirin) or selective COX-2 inhibitor therapy~* No concurrent anticoagulant drugs including, but not limited to, any of the following:~  * Warfarin~ * Heparin~ * Low-molecular weight heparin~ * Clopidogrel bisulfate~ * Extended-release dipyridamole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (placebo, esomeprazole magnesium) (Type: ACTIVE_COMPARATOR): Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
- Arm II (low-dose aspirin, esomeprazole magnesium) (Type: EXPERIMENTAL): Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
- Arm III (higher-dose aspirin, esomeprazole magnesium) (Type: EXPERIMENTAL): Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).